Follow us on:

Avacta Group Excellent data for the first clinical evaluation of lateral flow antigen test (Interview)

Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss first clinical evaluation of lateral flow antigen test. Alastair talks us through the data and explains the next steps in taking the test to market.

Find more news, interviews, share price & company profile here for:Avacta Group Plc

Share this interview

Other Interviews

More News

Avacta Group Potential for a COVID-19 Therapy May 15, 2020
Avacta Group Ships SARS-COV-2 Affimer Reagents to Cytiva and Adeptrix May 11, 2020
Avacta Group Strong revenue growth and cash position and multiple long term growth opportunities May 6, 2020
Avacta Group COVID-19 Antigen Diagnostic Collaboration with Adeptrix May 1, 2020
Avacta Group / Cytiva Partnership Ahead of Schedule for COVID-19 Antigen Rapid Test April 22, 2020
Avacta and Cytiva collaborating on COVID-19 Rapid Test April 8, 2020
Avacta Group Proposed Placing to raise £3.75 million April 6, 2020
Avacta Group plc To raise £2m to secure further significant drug development partnerships April 2, 2020
Avacta Group Shareholder and Investor Meeting and Presentation March 10, 2020
Avacta Group to hold Analyst Briefing February 13, 2020

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.